$CELC News

Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175

Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target

HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Stifel Maintains Buy on Celcuity, Lowers Price Target to $150

Needham Maintains Buy on Celcuity, Lowers Price Target to $140

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript

Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate

Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits

Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript

Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026

Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177

Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer

HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer

Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript